// App-Quantinova.ai

175 : Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal Phase III clinical trial data

Researchers

Presenter

  • Arvind Kaul

Principal Investigators

  • Vibeke Strand

  • Iain McInnes

  • Philip Mease

  • Ernest Choy

  • Peter Nash

  • Howard Thom

  • Chrysostomos Kalyvas

  • Kunal Gandhi

  • Luminita Pricop

  • Steffen Jugl

Medical Centers

  • Rheumatology, St George's Hospital and Medical School, London, UNITED KINGDOM

  • Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA

  • Division of Infection and Immunity, Cardiff University, Cardiff, UNITED KINGDOM

  • Faculty of Medicine, University of Queensland, Brisbane, AUSTRALIA

  • Bristol Medical School: Population Health Sciences, University of Bristol, Bristol, UNITED KINGDOM

  • Real World Strategy and Analytics, Mapi group, Houten, NETHERLANDS

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

  • Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ

  • Immunology & Dermatology Franchise, Novartis Pharma AG, Basel, SWITZERLAND

Locations

  • United Kingdom

  • United States

  • Australia

  • Netherlands

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Methotrexate

  • secukinumab

  • Infliximab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved